<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01240096</url>
  </required_header>
  <id_info>
    <org_study_id>S50181</org_study_id>
    <nct_id>NCT01240096</nct_id>
  </id_info>
  <brief_title>Mirtazapine Versus Placebo in Functional Dyspepsia</brief_title>
  <official_title>Phase 4 Study of Mirtazapine in Functional Dyspepsia Patients With Weight Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind randomized controlled trials of 8 weeks mirtazapine 15 mg daily or placebo,
      followed by 8 weeks of open-label mirtazapine 15 mg daily
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind randomized controlled trials of 8 weeks mirtazapine 15 mg or placebo, followed
      by 8 weeks of open-label mirtazapine

      Two weeks run-in, 8 weeks randomized, 8 weeks open label

      Assessments include

        -  dyspepsia questionnaire

        -  Nepean dyspepsia index

        -  Daily diary

        -  Vital signs
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2006</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in dyspepsia symptom scores week 8 versus week 0</measure>
    <time_frame>Week 8 compared to week 0</time_frame>
    <description>The Dyspepsia Symptom Score is calculated from the dyspepsia symptom severity questionnaire at weeks 0, 4 and 8. The symptom score has been used in previous studies (Tack et al., Gastroenterology 1998).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual symptom severities</measure>
    <time_frame>Week 8 compared to week 0</time_frame>
    <description>Individual symptom scores from the dyspepsia symptom score (DSS) which is used as primary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nepean dyspepsia index for quality of life in functional dyspepsia</measure>
    <time_frame>Week 8 compared to week 0</time_frame>
    <description>Use of the validated NDI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Mirtazapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mirtazapine 15 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirtazapine</intervention_name>
    <description>Mirtazapine 15 mg daily</description>
    <arm_group_label>Mirtazapine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>mirtazapine is Remergon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Functional dyspepsia according to Rome II criteria

          -  Weight loss of &gt; 5% body weights

        Exclusion Criteria:

          -  Organic GI pathology

          -  History of upper gi tract surgery

          -  Major depression or anxiety

          -  Use of antidepressants in the last 2 months

          -  Prokinetic drugs or spasmolytic drugs

          -  Analgesic use (except paracetamol)

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Tack, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Tack, M.D., Ph.D.</last_name>
    <phone>+3216344225</phone>
    <email>jan.tack@med.kuleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals</name>
      <address>
        <city>Leuven</city>
        <state>Vlaanderen</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Tack, M.D., Ph.D.</last_name>
      <phone>+3216344225</phone>
      <email>jan.tack@med.kuleuven.be</email>
    </contact>
    <investigator>
      <last_name>Jan Tack, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.targid.eu</url>
    <description>Website Research Group</description>
  </link>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2010</study_first_submitted>
  <study_first_submitted_qc>November 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <last_update_submitted>November 12, 2010</last_update_submitted>
  <last_update_submitted_qc>November 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jan Tack, M.D., Ph.D.</name_title>
    <organization>University Hospitals Leuven</organization>
  </responsible_party>
  <keyword>Functional dyspepsia</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Mirtazapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Mianserin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

